Benefits
Circulating stem cell counts after a single dose
In a placebo-controlled crossover in 12 healthy adults, one 500 mg dose raised some blood stem cell counts from baseline within 2 hours, but the paper's figures show no significant difference from placebo at the fixed time points. A positive result came only from an added analysis of each person's peak response. The study was co-sponsored by a company led by its lead author, and no health outcome was measured.
Antioxidant activity in cell studies
In cell culture studies by Puredia-affiliated authors, the extract reduced hydrogen peroxide damage in macrophages and retinal cells. The maker cites an ORAC value about 9 times that of grape seed extract. ORAC is a test-tube measure, and the USDA removed its ORAC database in 2012, saying such values have no relevance to effects on human health. No human antioxidant outcome has been tested.
Skin and blood vessel cell effects in lab and mouse studies
In a study by Puredia-affiliated authors, sea buckthorn proanthocyanidins given by mouth to mice with chemically induced aging improved skin aging measures and raised total antioxidant capacity. In cultured blood vessel lining cells, they reduced damage from palmitic acid. No human skin or circulation trial of CyanthOx has been published.
Proanthocyanidin makeup of sea buckthorn extracts
A review describes sea buckthorn proanthocyanidins as built mainly from gallocatechin and epigallocatechin units (prodelphinidins), which sets them apart from grape seed proanthocyanidins. A Puredia-affiliated analysis found the maker's extract to be mainly epicatechin gallate and dimers built from catechin and gallocatechin units. Whether this changes absorption or effects in people has not been tested.
A different fraction from sea buckthorn oil and juice
CyanthOx is a water-soluble polyphenol extract, not the oil or the whole berry. Human trials of sea buckthorn oil, berries, juice, puree and a hydroethanolic fruit extract, described in the separate Sea Buckthorn entry, studied other products, and their results do not transfer to this extract.
Mechanism of action
Proanthocyanidin structure
Proanthocyanidins are chains of flavan-3-ol units. Sea buckthorn proanthocyanidins are built from catechin, epicatechin, gallocatechin and epigallocatechin units linked by B-type bonds; gallocatechin units carry an extra hydroxyl group and form prodelphinidins. The maker's extract also contains flavonols such as quercetin and kaempferol.
Nrf2 and mitochondrial pathways in cells
In macrophages exposed to hydrogen peroxide, the extract raised mitochondrial membrane potential and activated the AMPK, PGC-1α and Nrf2 pathway. In retinal pigment cells, it activated Nrf2 and HO-1 signaling and restored superoxide dismutase activity. These were cell studies with Puredia-affiliated authors, at concentrations not shown to occur after an oral dose.
Stem cell release hypothesis
The authors of the human study proposed that the extract releases stem cells from bone marrow into the blood. This was inferred from blood counts over 2 hours; no mechanism was tested, the fixed time point comparisons with placebo were not significant, and the result has not been repeated by an independent group.
Absorption of oligomers versus polymers
A review of sea buckthorn proanthocyanidins notes that human absorption data for its oligomers versus polymers are scarce and that, from the wider proanthocyanidin literature, smaller oligomers are thought to be better absorbed than polymers. How much of CyanthOx reaches the blood has not been measured.
Clinical trials
Randomized, double-blind, placebo-controlled crossover with visits at least 1 week apart: one 500 mg capsule of a Puredia sea buckthorn berry proanthocyanidin extract (identified by Puredia as CyanthOx 30) or rice flour placebo, with blood drawn at baseline, 1 hour and 2 hours. Co-sponsored by Biomx StemCeuticals, whose co-founder was the lead author, and NIS Labs, whose research director was a co-author and which ran the study. The registry entry (NCT03388073) also lists 250 mg and berry blend arms that the paper does not report. (Drapeau et al. 2019, Clin Interv Aging)
12 healthy adults (8 women, 4 men) aged 28 to 70.
At the fixed 1 and 2 hour time points, the paper's figures report no significant difference from placebo for CD45dim CD34+ CD309 negative progenitor cells (P<0.17), CD31+ endothelial cells or CD90+ cells, although the text reports P<0.04 and P<0.05 for endothelial cells. Progenitor cells rose from baseline at 2 hours. An added analysis of each person's peak response, adjusted for placebo, reported rises of about 20% to 33%. Adverse events were not reported.